Takeda and Seattle Genetics report positive results from Phase III ALCANZA trial of Adcetris to treat CTCL
Takeda Pharmaceutical and Seattle Genetics have reported positive results from the Phase III ALCANZA clinical trial of Adcetris to treat cutaneous T-cell lymphoma (CTCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Cutaneous T cell lymphoma | Genetics | Lymphoma | Pharmaceuticals | T-cell Lymphoma